Dr. Park is a physician-scientist with expertise in molecular targets for cancer, including circulating plasma tumor DNA as biomarkers for detecting residual disease, which is known as a ‘liquid biopsy.’ He is a leader in the field of PIK3CA gene mutations and their relevance to breast cancer. In 2004, he was the first to identify a high frequency of PIK3CA mutations in breast cancer and then discovered their contributions towards oncogenic phenotypes. His work, including the generation of genetically modified cell lines, has been widely cited, and requests for his cell lines have led to important discoveries by other investigators. Dr. Park also has made fundamental contributions to the field of drug resistance, including hormone therapy resistance. Along with colleagues, he holds several patents for the discovery of unique compounds used in treating various diseases. His research is supported by funding from the National Cancer Institute (a division of the National Institutes of Health), the Avon Foundation, the Breast Cancer Research Foundation, and the Susan G. Komen Foundation. He has been the recipient of numerous foundation awards, including the V Foundation, American Cancer Society, the Elsa U. Pardee Foundation, as well as the Department of Defense. He also has been named a Komen Scholar and is a member of the American Society for Clinical Investigation (ASCI).
Ben Ho Park, MD, PhD
Donna S. Hall Professor of Medicine
Director, Division of Hematology and Oncology
Johns Hopkins University
Professor of Oncology, Associate Director for Research Training and Education SKCC, Associate Dean
MD - The University of Pennsylvania
Ph.D. - The University of Pennsylvania